We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Citations Search

Sort By:

MAbs 10(3), 370-379. Development and characterization of an anti-rituximab monoclonal antibody panel.


Tada, M., Suzuki, T., and Ishii-Watabe, A.


Notes: These authors used the CytoTox®-Glo Assay as the readout for a CDC assay, and the ADCC reporter bioassay, to evaluate the potency of anti-rituximab antibodies. 


Expand Full Notes »

J. Biol. Chem. 291(53), 27134–46. Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. 2016

Zhang, D., Goldberg, M. V. and Chiu, M. L.

Notes: Agonist antibodies targeting T cells and other immune cells to simulate immune activation have shown to be promising for cancer therapeutics. Here, the NanoBRET™ Protein-Protein Interaction Assay was used to measure hexamerization of anti-OX40 antibodies on the cell surface. Specific anti-OX40 antibody mutations were analyzed for increased antibody multimerization and engagement. Mutations promoting IgG hexamerization showed enhanced agonistic activity. (5056)

Expand Full Notes »